Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gammaitoni

Showing results (151-160 of 230) with videos related to

Pageof 23
Sort By:
Cancers|November 14, 2023
Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab TreatmentMarco Carlo Merlano, Matteo Paccagnella, Nerina Denaro, et al.
Epilepsy & Behavior : E&B|May 23, 2021
Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndromeKim I Bishop, Peter K Isquith, Gerard A Gioia, et al.
Melanoma Research|December 13, 2017
BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case reportSusanna Gallo, Valentina Coha, Daniela Caravelli, et al.
Pain|December 28, 2010
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic painDavid J Hewitt, Tony W Ho, Bradley Galer, et al.
Blood|November 28, 2002
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficientWanda Piacibello, Stefania Bruno, Fiorella Sanavio, et al.
Epilepsia|October 20, 2020
Fenfluramine HCl (Fintepla<sup>®</sup> ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension studyJoseph Sullivan, Ingrid E Scheffer, Lieven Lagae, et al.
The Journal of Rheumatology|March 17, 2012
How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom?Nigel K Arden, A Brett Hauber, Ateesha F Mohamed, et al.
Osteoarthritis and Cartilage|November 28, 2012
A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritisA B Hauber, N K Arden, A F Mohamed, et al.
Epilepsia Open|July 8, 2022
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access ProgramRenzo Guerrini, Nicola Specchio, Ángel Aledo-Serrano, et al.
Stem Cells (Dayton, Ohio)|March 29, 2008
Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectorsMelania Tesio, Loretta Gammaitoni, Monica Gunetti, et al.
Pageof 23

Showing results (151-160 of 230) with videos related to

Sort By:
Pageof 23
Cancers|November 14, 2023
Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab TreatmentMarco Carlo Merlano, Matteo Paccagnella, Nerina Denaro, et al.
Epilepsy & Behavior : E&B|May 23, 2021
Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndromeKim I Bishop, Peter K Isquith, Gerard A Gioia, et al.
Melanoma Research|December 13, 2017
BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case reportSusanna Gallo, Valentina Coha, Daniela Caravelli, et al.
Pain|December 28, 2010
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic painDavid J Hewitt, Tony W Ho, Bradley Galer, et al.
Blood|November 28, 2002
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficientWanda Piacibello, Stefania Bruno, Fiorella Sanavio, et al.
Epilepsia|October 20, 2020
Fenfluramine HCl (Fintepla<sup>®</sup> ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension studyJoseph Sullivan, Ingrid E Scheffer, Lieven Lagae, et al.
The Journal of Rheumatology|March 17, 2012
How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom?Nigel K Arden, A Brett Hauber, Ateesha F Mohamed, et al.
Osteoarthritis and Cartilage|November 28, 2012
A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritisA B Hauber, N K Arden, A F Mohamed, et al.
Epilepsia Open|July 8, 2022
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access ProgramRenzo Guerrini, Nicola Specchio, Ángel Aledo-Serrano, et al.
Stem Cells (Dayton, Ohio)|March 29, 2008
Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectorsMelania Tesio, Loretta Gammaitoni, Monica Gunetti, et al.
Pageof 23